|
US6749868B1
(en)
|
1993-02-22 |
2004-06-15 |
American Bioscience, Inc. |
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
|
|
US6979456B1
(en)
|
1998-04-01 |
2005-12-27 |
Jagotec Ag |
Anticancer compositions
|
|
IL141095A0
(en)
|
1998-08-19 |
2002-02-10 |
Rtp Pharma Inc |
Injectable aqueous dispersions of propofol
|
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
|
WO2003080027A1
(en)
*
|
2002-03-20 |
2003-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
|
US20080220075A1
(en)
*
|
2002-03-20 |
2008-09-11 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
|
AU2003286725B2
(en)
*
|
2002-10-29 |
2007-07-12 |
Transform Pharmaceuticals, Inc. |
Propofol with cysteine
|
|
LT1585548T
(lt)
|
2002-12-09 |
2018-09-25 |
Abraxis Bioscience, Llc |
Farmakologinių agentų kompozicijos ir įvedimo būdai
|
|
US7468394B1
(en)
*
|
2003-03-11 |
2008-12-23 |
Amphastar Pharmaceuticals, Inc. |
Sterile pharmaceutical composition and process for a solution of propofol emulsion having microbial growth retardation
|
|
US20040225022A1
(en)
*
|
2003-05-09 |
2004-11-11 |
Desai Neil P. |
Propofol formulation containing reduced oil and surfactants
|
|
US8476010B2
(en)
*
|
2003-07-10 |
2013-07-02 |
App Pharmaceuticals Llc |
Propofol formulations with non-reactive container closures
|
|
US8546453B2
(en)
|
2003-08-14 |
2013-10-01 |
Rensheng Zhang |
Propofol compositions and methods for reducing pain associated with propofol injection
|
|
RU2290169C1
(ru)
*
|
2005-06-23 |
2006-12-27 |
Открытое Акционерное Общество "Фаберлик" |
Косметическое и/или дерматологическое средство и антиоксидант
|
|
SI3311805T1
(sl)
|
2005-08-31 |
2020-07-31 |
Abraxis Bioscience, Llc |
Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva
|
|
BRPI0615292A8
(pt)
*
|
2005-08-31 |
2018-03-06 |
Abraxis Bioscience Llc |
composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
|
|
CN101411685B
(zh)
*
|
2007-10-19 |
2011-04-20 |
上海医药工业研究院 |
一种静脉麻醉药2,6-二异丙基苯酚微乳组合物及其制备方法
|
|
MX2012010684A
(es)
|
2010-03-17 |
2012-11-06 |
Novaliq Gmbh |
Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
|
|
EP2444063A1
(en)
|
2010-10-20 |
2012-04-25 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the delivery of active ingredients
|
|
EP2462921A1
(en)
|
2010-11-11 |
2012-06-13 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the treatment of a posterior eye disease
|
|
CA2819988C
(en)
*
|
2011-01-04 |
2019-11-12 |
Novaliq Gmbh |
O/w-emulsions comprising semifluorinated alkanes
|
|
KR101903351B1
(ko)
*
|
2011-03-04 |
2018-10-04 |
그뤼넨탈 게엠베하 |
타펜타돌의 비경구 투여
|
|
JP2019142972A
(ja)
*
|
2011-03-04 |
2019-08-29 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
タペンタドールの非経口的投与
|
|
JP6046057B2
(ja)
|
2011-03-04 |
2016-12-14 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
経口投与用タペンタドールの水性医薬製剤
|
|
JP6027549B2
(ja)
|
2011-03-04 |
2016-11-16 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
タペンタドールを含む半固形の水性医薬組成物
|
|
EP3192501B1
(en)
|
2011-05-25 |
2020-05-13 |
Novaliq GmbH |
Topical pharmaceutical composition based on semifluorinated alkanes
|
|
JP2013001700A
(ja)
*
|
2011-06-21 |
2013-01-07 |
Fujifilm Corp |
プロポフォール含有水中油型エマルション組成物
|
|
JP5759804B2
(ja)
*
|
2011-06-27 |
2015-08-05 |
富士フイルム株式会社 |
容器詰製剤
|
|
WO2013110621A1
(en)
|
2012-01-23 |
2013-08-01 |
Novaliq Gmbh |
Stabilised protein compositions based on semifluorinated alkanes
|
|
MX374014B
(es)
|
2012-05-16 |
2020-07-24 |
Mewa Singh |
Composiciones farmaceuticas para la entrega de farmacos insolubles en agua.
|
|
BR112015004997B1
(pt)
|
2012-09-12 |
2022-09-13 |
Novaliq Gmbh |
Composições oftálmicas contendo misturas de alcanos semifluorados
|
|
JP6039152B2
(ja)
|
2012-09-12 |
2016-12-07 |
ノバリック ゲーエムベーハー |
半フッ素化アルカン組成物
|
|
CN114028560A
(zh)
|
2013-07-23 |
2022-02-11 |
诺瓦利克有限责任公司 |
稳定的抗体组合物
|
|
MX2017012312A
(es)
|
2015-03-27 |
2018-01-18 |
Gruenenthal Gmbh |
Formulacion estable para administracion parenteral de tapentadol.
|
|
EP3331567B1
(en)
*
|
2015-07-24 |
2020-09-23 |
Neon Laboratories Ltd. |
Stabilized injectable emulsion of propofol and ketamine
|
|
US11622937B2
(en)
|
2015-08-20 |
2023-04-11 |
Mewa Singh |
Polyphenolic polymer to make water-insoluble molecules become water-soluble
|
|
CN110403923B
(zh)
|
2015-09-30 |
2021-09-21 |
诺瓦利克有限责任公司 |
半氟化化合物和其组合物
|
|
WO2017055453A1
(en)
|
2015-09-30 |
2017-04-06 |
Novaliq Gmbh |
Semifluorinated compounds for ophthalmic administration
|
|
PT3442480T
(pt)
|
2016-06-23 |
2019-12-23 |
Novaliq Gmbh |
Método de administração tópica
|
|
EP3515420B1
(en)
|
2016-09-22 |
2023-11-08 |
Novaliq GmbH |
Pharmaceutical compositions for use in the therapy of blepharitis
|
|
AU2017329983B2
(en)
|
2016-09-23 |
2022-05-05 |
Novaliq Gmbh |
Ophthalmic compositions comprising ciclosporin
|
|
WO2018055070A1
(en)
|
2016-09-23 |
2018-03-29 |
Grünenthal GmbH |
Stable formulation for parenteral administration of tapentadol
|
|
BR112019012791A2
(pt)
|
2016-12-23 |
2019-12-03 |
Novaliq Gmbh |
composição oftálmica para o tratamento da doença do olho seco
|
|
CN110678207B
(zh)
|
2017-04-21 |
2024-08-02 |
德马利克治疗公司 |
碘组合物
|
|
WO2018206656A1
(en)
|
2017-05-12 |
2018-11-15 |
Novaliq Gmbh |
Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
|
|
EP3687496A1
(en)
|
2017-09-27 |
2020-08-05 |
Novaliq GmbH |
Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
|
|
CN120022260A
(zh)
|
2017-10-04 |
2025-05-23 |
诺瓦利克有限责任公司 |
包含f6h8的眼用组合物
|
|
KR20200128407A
(ko)
|
2018-03-02 |
2020-11-12 |
노바리크 게엠베하 |
네비볼롤을 포함하는 약제학적 조성물
|
|
CN112153970A
(zh)
|
2018-04-27 |
2020-12-29 |
诺瓦利克有限责任公司 |
用于治疗青光眼的包含他氟前列素的眼用组合物
|
|
WO2020074697A1
(en)
|
2018-10-12 |
2020-04-16 |
Novaliq Gmbh |
Ophthalmic composition for treatment of dry eye disease
|
|
EP3923907B1
(en)
|
2019-02-13 |
2024-09-25 |
Novaliq GmbH |
Compositions and methods for the treatment of ocular neovascularization
|